Tumor response to EGFR/BRAF/MEK co-inhibition in a patient with EGFR mutated lung adenocarcinoma developing a BRAF

Autor: Charlotte, Mauclet, Philippe, Collard, Benoit, Ghaye, Delphine, Hoton, Frank Aboubakar, Nana

Publikováno v: Lung cancer (Amsterdam, Netherlands). 159

EGFR-mutant adenocarcinomas represent 12% of unselected lung adenocarcinomas and 44% of never smoker adenocarcinomas in the Caucasian population. Activating mutations like exon19 deletion or exon21 Leu858Arg point mutations are predictive of tumor re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f9b961732c008292e94dda0e7cf4616f
https://pubmed.ncbi.nlm.nih.gov/34304052

Complete tumor response of a locally advanced lung large-cell neuroendocrine carcinoma after palliative thoracic radiotherapy and immunotherapy with nivolumab

Autor: Vincent Remouchamps, Claudia Pop-Stanciu, Myriam Remmelink, Marie Wanet, Lionel Pirard, Michaël Dupont, Charlotte Mauclet, Nicky D'Haene, Suzan Lambin, Benoît Rondelet, Thierry Vander Borght, Fabrice Duplaquet, Sebahat Ocak

Publikováno v: Lung cancer: journal of the International Association for the Study of Lung Cancer
Lung cancer, Vol. 128, p. 53-56 (2019)

Lung large-cell neuroendocrine carcinoma (L-LCNEC) is a rare subset of lung carcinoma associated with poor overall survival. Due to its rarity, little has been established about its optimal treatment in the advanced stage. We report the case of a 41-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ba41a474773b510f343c4542f136ea6
https://repository.uantwerpen.be/docman/irua/158ce0/157531_2019_08_01.pdf